Acute Respiratory Distress Syndrome News and Research RSS Feed - Acute Respiratory Distress Syndrome News and Research

New tool can help doctors identify patients at highest risk for respiratory failure after surgery

New tool can help doctors identify patients at highest risk for respiratory failure after surgery

A new prediction tool can help doctors better identify patients who are at highest risk for respiratory failure after surgery and therefore prevent the often deadly condition, suggest data from a large multi-center study published in the May issue of Anesthesiology. [More]

Study helps physicians better identify patients at risk of acute respiratory distress syndrome

Acute respiratory distress syndrome is a leading cause of respiratory failure after surgery. Patients who develop the lung disorder postoperatively are at higher risk of dying in the hospital, and those who survive the syndrome may still bear its physical effects years later. [More]

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates. [More]
Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Research indicated that some Indigenous people such as in Alaska and Australia displayed limited immunity response to the effects of influenza. [More]

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million. [More]
Phase 2 study to explore safety and efficacy of H.P. Acthar Gel for ARDS

Phase 2 study to explore safety and efficacy of H.P. Acthar Gel for ARDS

Questcor Pharmaceuticals, Inc. announced today that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome. [More]

Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate its AEROSURF phase 2 clinical program. [More]

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. [More]
Emerging H7N9 virus has potential to cause a pandemic

Emerging H7N9 virus has potential to cause a pandemic

A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts. [More]
Fixed-ratio transfusion protocol in trauma patients is feasible, but wastes blood plasma

Fixed-ratio transfusion protocol in trauma patients is feasible, but wastes blood plasma

The use of a 1:1:1 blood transfusion protocol in patients with severe trauma is feasible in hospitals, although it is associated with higher waste of plasma, according to a randomized trial published in CMAJ (Canadian Medical Association Journal). [More]
H7 influenza may spillover repeatedly into humans, say scientists

H7 influenza may spillover repeatedly into humans, say scientists

The H7N9 avian flu strain that emerged in China earlier this year has subsided for now, but it would be a mistake to be reassured by this apparent lull in infections. The virus has several highly unusual traits that paint a disquieting picture of a pathogen that may yet lead to a pandemic, according to lead scientists from the National Institute of Allergy and Infectious Diseases. [More]
Study describes radiologic findings in H7N9 pneumonia

Study describes radiologic findings in H7N9 pneumonia

H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology. [More]
Researchers identify novel biomarkers for predicting mortality in ICU patients

Researchers identify novel biomarkers for predicting mortality in ICU patients

A metabolic profile of intensive care unit patients based on biomarkers of four metabolites can be used to accurately predict mortality, according to a new study. [More]
Inflammation and epigenetics: an interview with Dr Belkina and Dr Denis, Boston University School of Medicine

Inflammation and epigenetics: an interview with Dr Belkina and Dr Denis, Boston University School of Medicine

Inflammation can be thought of as taking two major forms: acute or chronic. Acute inflammation, which can be painful, usually arises quickly and resolves quickly. It accompanies bacterial infections, traumatic injury and is useful to fight infections and promote healing. [More]
High-frequency oscillatory ventilation put on hold

High-frequency oscillatory ventilation put on hold

Findings from two trials suggest that high-frequency oscillatory ventilation does not help, and may even harm patients with acute respiratory distress syndrome. [More]
Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer. [More]

Spotlight on acute respiratory distress syndrome in low-risk surgery

Postoperative acute respiratory distress syndrome is rare in patients undergoing low-risk surgery, but still carries a very high mortality rate, a large study shows. [More]

WHO assists Middle East authorities with coronavirus investigation

The World Health Organization has sent a team to Jordan at the request of the country’s Ministry of Health to help investigate the emergence of a novel coronavirus that resulted in the deaths of two people earlier this year, and to assist with further epidemiologic surveillance. [More]
Procalcitonin levels help distinguish between pneumonia types

Procalcitonin levels help distinguish between pneumonia types

Serum procalcitonin is a useful marker for distinguishing between acute exacerbation of interstitial pneumonia and bacterial pneumonia, say researchers. [More]

Patients without lung injury may benefit from mechanical ventilation with lower tidal volume use

Among patients without acute respiratory distress syndrome, protective mechanical ventilation with use of lower tidal volumes (the volume of air inhaled and exhaled during each breath) was associated with better outcomes including less lung injury, lower mortality, fewer pulmonary infections and a shorter hospital length of stay, according to a meta-analysis of previous studies, reported in the October 24/31 issue of JAMA. [More]